Elevation Oncology Inc
NASDAQ:ELEV
Elevation Oncology Inc
Capital Expenditures
Elevation Oncology Inc
Capital Expenditures Peer Comparison
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Elevation Oncology Inc
NASDAQ:ELEV
|
Capital Expenditures
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Capital Expenditures
-$795m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-4%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Capital Expenditures
-$581m
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-6%
|
|
Amgen Inc
NASDAQ:AMGN
|
Capital Expenditures
-$998m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Capital Expenditures
-$464.7m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
-25%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Capital Expenditures
-$809.1m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
See Also
What is Elevation Oncology Inc's Capital Expenditures?
Capital Expenditures
0
USD
Based on the financial report for Dec 31, 2023, Elevation Oncology Inc's Capital Expenditures amounts to 0 USD.